The weak market for antimicrobials could be revived by a new $11bn US government-funded plan embedded in the draft Cures 2.0 legislation that would guarantee revenue for certain treatments regardless of the number of prescriptions sold.
Supporters of the plan, the bipartisan PASTEUR Act, believe the measure would lead to a new wave of private investment in the